Specify a stock or a cryptocurrency in the search bar to get a summary
Rezolute Inc
RZLTRezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company's lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Address: 275 Shoreline Drive, Redwood City, CA, United States, 94065
Analytics
WallStreet Target Price
13 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures RZLT
Dividend Analytics RZLT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History RZLT
Stock Valuation RZLT
Financials RZLT
Results | 2019 | Dynamics |